Navigation Links
Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
Date:10/3/2007

A Fully Automated, Portable Solution for In-Clinic and Out-Reach Influenza

Testing

PORTON DOWN, England, October 3 /PRNewswire/ -- Enigma Diagnostics, the life sciences company developing rapid molecular diagnostics and detection systems, announces a EUR3 million award from the European Commission Framework 7 programme to the RANGER consortium. The award will fund the development and validation of a fully automated, low cost system for the rapid diagnosis of influenza infections and subtypes.

The RANGER consortium, which is coordinated by Enigma Diagnostics, comprises leading technology companies including Applied Biosystems, Sagentia, Tico Europe, Bruhn Newtech Group, Bioplastics BV and PERA who will contribute to the development of the instrument and assays. The consortium also includes the Health Protection Agency, the UK's national reference laboratory for influenza diagnostics, and the Queen Sirikit National Institute of Child Health who will evaluate and validate the system.

The system will be based on Enigma's proprietary and fully-automated instrumentation technology, which integrates sample preparation with real-time polymerase chain reaction (PCR) to detect viral RNA in a full range of clinical samples. The simple-to-use, portable system will provide rapid results direct to medical staff in a near-patient or out-reach environment in both the developed and developing world.

By providing laboratory standard, high specificity and sensitivity PCR results in a decentralised setting, the system will advance the diagnosis of early stage viral infections and the surveillance of disease outbreaks.

Enigma is also separately developing real-time PCR-based diagnostics systems targeting chlamydia, gonorrhoea and other sexually transmitted infections.

John McKinley, Chairman of Enigma Diagnostics, said: "The award of this grant and the strength of our consortium partners is a great endorsement of Enigma's technology. It is also a strategically important milestone for the company as it demonstrates the utility of our real time PCR in what is an extremely challenging area of diagnosis. We are confident we will be able to deliver a system that rapidly and simply delivers laboratory quality results at the point of care."


'/>"/>
SOURCE Enigma Diagnostics Limited
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Roche Diagnostics Corporation
2. Roche Diagnostics Corporation
3. A prognosis for GE and Abbott Diagnostics
4. The world of in-vitro diagnostics is another Midwest success story
5. The world of in vitro diagnostics is another Midwest success story
6. Midwest holds strong position in worldwide diagnostics business
7. BioDiagnostics is first seed-testing lab to gain new accreditation
8. Speaker announces business members of IT Task Force
9. Doyle announces technology tax credits for Berbee
10. Doyle announces new energy, global warming policies
11. Doyle announces $80M renewable energy strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... Toronto, Canada (PRWEB) , ... May 23, 2017 ... ... of Firmex FileSend, a cloud-based file transfer solution that makes it easy for ... firewall without having to worry about cumbersome FTP software or email file size ...
(Date:5/23/2017)... Ca (PRWEB) , ... May ... ... (PSCs) offer an unlimited source of human cardiovascular cells for research and ... differentiation methods makes it possible to generate large numbers of cardiomyocytes (hPSC-CMs). ...
(Date:5/23/2017)... ... 2017 , ... NetDimensions has been ranked as a Leader ... Corporate Learning, 2017. , Aragon Research defines Leaders as organizations who possess comprehensive ... those strategies. NetDimensions’ ranking as a Leader due to its strengths in: , ...
(Date:5/23/2017)... PARK, CA (PRWEB) , ... May 23, 2017 , ... ... the publication of “Label-free isolation of prostate circulating tumor cells using Vortex microfluidic ... is the result of a collaboration with Dr. Dino Di Carlo and Dr. Matthew ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by Solution ... Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to 2022", ... 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at a ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):